280 related articles for article (PubMed ID: 14629982)
1. Characteristics of the Plasmodium falciparum PK5 ATP-binding site: implications for the design of novel antimalarial agents.
Keenan SM; Welsh WJ
J Mol Graph Model; 2004 Jan; 22(3):241-7. PubMed ID: 14629982
[TBL] [Abstract][Full Text] [Related]
2. A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors.
Bhattacharjee AK; Geyer JA; Woodard CL; Kathcart AK; Nichols DA; Prigge ST; Li Z; Mott BT; Waters NC
J Med Chem; 2004 Oct; 47(22):5418-26. PubMed ID: 15481979
[TBL] [Abstract][Full Text] [Related]
3. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design.
Schulze-Gahmen U; De Bondt HL; Kim SH
J Med Chem; 1996 Nov; 39(23):4540-6. PubMed ID: 8917641
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones.
Geyer JA; Keenan SM; Woodard CL; Thompson PA; Gerena L; Nichols DA; Gutteridge CE; Waters NC
Bioorg Med Chem Lett; 2009 Apr; 19(7):1982-5. PubMed ID: 19250824
[TBL] [Abstract][Full Text] [Related]
5. Elucidation of sulfadoxine resistance with structural models of the bifunctional Plasmodium falciparum dihydropterin pyrophosphokinase-dihydropteroate synthase.
de Beer TA; Louw AI; Joubert F
Bioorg Med Chem; 2006 Jul; 14(13):4433-43. PubMed ID: 16517168
[TBL] [Abstract][Full Text] [Related]
6. Structural insights into the Plasmodium falciparum histone deacetylase 1 (PfHDAC-1): A novel target for the development of antimalarial therapy.
Mukherjee P; Pradhan A; Shah F; Tekwani BL; Avery MA
Bioorg Med Chem; 2008 May; 16(9):5254-65. PubMed ID: 18362073
[TBL] [Abstract][Full Text] [Related]
7. Targeting malaria with specific CDK inhibitors.
Geyer JA; Prigge ST; Waters NC
Biochim Biophys Acta; 2005 Dec; 1754(1-2):160-70. PubMed ID: 16185941
[TBL] [Abstract][Full Text] [Related]
8. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
Marrero-Ponce Y; Iyarreta-Veitía M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
[TBL] [Abstract][Full Text] [Related]
9. Generation and evaluation of a homology model of PfGSK-3.
Kruggel S; Lemcke T
Arch Pharm (Weinheim); 2009 Jun; 342(6):327-32. PubMed ID: 19475596
[TBL] [Abstract][Full Text] [Related]
10. Identification of an effector protein and gain-of-function mutants that activate Pfmrk, a malarial cyclin-dependent protein kinase.
Chen Y; Jirage D; Caridha D; Kathcart AK; Cortes EA; Dennull RA; Geyer JA; Prigge ST; Waters NC
Mol Biochem Parasitol; 2006 Sep; 149(1):48-57. PubMed ID: 16737745
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of fructose-1,6-bisphosphate aldolase from the human malaria parasite Plasmodium falciparum.
Kim H; Certa U; Döbeli H; Jakob P; Hol WG
Biochemistry; 1998 Mar; 37(13):4388-96. PubMed ID: 9521758
[TBL] [Abstract][Full Text] [Related]
12. Comparative protein modeling of 1-deoxy-D-xylulose-5-phosphate reductoisomerase enzyme from Plasmodium falciparum: a potential target for antimalarial drug discovery.
Singh N; Chevé G; Avery MA; McCurdy CR
J Chem Inf Model; 2006; 46(3):1360-70. PubMed ID: 16711755
[TBL] [Abstract][Full Text] [Related]
13. In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase.
Fogel GB; Cheung M; Pittman E; Hecht D
J Mol Graph Model; 2008 Apr; 26(7):1145-52. PubMed ID: 18037315
[TBL] [Abstract][Full Text] [Related]
14. Model of the TBP-TFIIB complex from Plasmodium falciparum: interface analysis and perspectives as a new target for antimalarial design.
Buendía-Orozco J; Guerrero A; Pastor N
Arch Med Res; 2005; 36(4):317-30. PubMed ID: 15950069
[TBL] [Abstract][Full Text] [Related]
15. In silico Screening and Evaluation of Plasmodium falciparum Protein Kinase 5 (PK5) Inhibitors.
Eubanks AL; Perkins MM; Sylvester K; Ganley JG; Posfai D; Sanschargrin PC; Hong J; Sliz P; Derbyshire ER
ChemMedChem; 2018 Dec; 13(23):2479-2483. PubMed ID: 30328274
[TBL] [Abstract][Full Text] [Related]
16. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
[TBL] [Abstract][Full Text] [Related]
17. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development.
Waters NC; Geyer JA
Expert Opin Ther Targets; 2003 Feb; 7(1):7-17. PubMed ID: 12556199
[TBL] [Abstract][Full Text] [Related]
19. Crystal structures of mammalian glutamine synthetases illustrate substrate-induced conformational changes and provide opportunities for drug and herbicide design.
Krajewski WW; Collins R; Holmberg-Schiavone L; Jones TA; Karlberg T; Mowbray SL
J Mol Biol; 2008 Jan; 375(1):217-28. PubMed ID: 18005987
[TBL] [Abstract][Full Text] [Related]
20. A novel computational analysis of ligand-induced conformational changes in the ATP binding sites of cyclin dependent kinases.
Subramanian J; Sharma S; B-Rao C
J Med Chem; 2006 Sep; 49(18):5434-41. PubMed ID: 16942017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
